- Also known as
- CJC 1295 ipamorelin · CJC-1295/Ipamorelin · Mod GRF 1-29 + ipamorelin · CJC 1295 no DAC and ipamorelin
- Class
- Two-peptide research blend: a GHRH analogue and a ghrelin receptor (GHS-R) agonist
- Form
- Lyophilised powder supplied in 10 mg vials
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
What is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin ships as a single vial of lyophilised powder containing CJC-1295 (no DAC) 5 mg, Ipamorelin 5 mg and CJC-1295 with DAC (reference studies) 0 mg. The components carry separate literatures, and the references gathered here are those separate studies. The chain extends to 5 amino acids. The published record covers rat, human and DAC-study human work. Of the 8 references listed below, 2 are controlled human trials. It comes as lyophilised powder in 10 mg vials, kept in Canadian stock for laboratory research. It is not a medicine and is not for use in humans or animals.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Gobburu JV et al.1999 · Pharm Res · PMID 10496658 | Human, randomised dose-escalation PK/PD trial (healthy men, 8 per dose level, 5 dose levels) | 4.21, 14.02, 42.13, 84.27 or 140.45 nmol/kg infused over 15 minutes | Single infusion | Ipamorelin had a terminal half-life of 2 hours and dose-proportional pharmacokinetics. Each dose produced a single episode of growth hormone release peaking at 0.67 hours, then an exponential decline to negligible levels. |
| Beck DE et al.2014 · Int J Colorectal Dis · PMID 25331030 | Human, phase 2 randomised, double-blind, placebo-controlled trial (n=114 analysed, bowel resection patients) | 0.03 mg/kg intravenous infusion, twice daily | Postoperative day 1 to 7 or hospital discharge | Treatment-emergent adverse events occurred in 87.5% on ipamorelin and 94.8% on placebo. Median time to first tolerated meal was 25.3 vs 32.6 hours (p = 0.15), and no efficacy analysis differed significantly from placebo. |
| Raun K et al.1998 · Eur J Endocrinol · PMID 9849822 | Rat pituitary cells in vitro; anaesthetised rats; conscious swine | ED50 for GH release 80 nmol/kg in rats and 2.3 nmol/kg in swine; specificity tested at more than 200-fold the ED50 | Single doses | Ipamorelin released growth hormone with potency and efficacy similar to GHRP-6. Unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol, and it did not affect FSH, LH, prolactin or TSH in swine. |
| Johansen PB et al.1999 · Growth Horm IGF Res · PMID 10373343 | Rat, adult females | 0, 18, 90 or 450 micrograms/day s.c., given three times daily | 15 days | Longitudinal bone growth rose dose-dependently from 42 to 44, 50 and 52 micrometres/day, with a dose-dependent gain in body weight. Total IGF-I, IGFBPs and bone turnover markers did not change. |
| Rafferty B et al.1985 · J Endocrinol · PMID 2866222 | Rat (anaesthetised), pharmacokinetic study of native hGRF(1-29)NH2, the unmodified parent of CJC-1295 without DAC | 10 micrograms i.v.; s.c. dose not stated in the abstract | Single dose | After i.v. injection the peptide cleared with half-lives of 1.9 min (distribution) and 10.4 min (elimination). After s.c. injection the amount reaching the circulation was only 4% of the i.v. amount. |
| Cervini LA et al.1998 · J Med Chem · PMID 9513600 | In vitro structure-activity study of hGRF(1-29)-NH2 analogues (growth hormone release) | Not stated in the abstract | Not applicable (in vitro) | Single alanine swaps at positions 8, 9, 15, 22 and 28 gave analogues 2-6 times more potent than hGRF(1-40)-OH, and multiple-substituted analogues were 11 to 26 times more effective. This is the design family Mod GRF 1-29 belongs to; the no-DAC compound itself was not tested. |
| Teichman SL et al.2006 · J Clin Endocrinol Metab · PMID 16352683 | DAC STUDY. Human, two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21-61 (n not stated in the abstract). Tested CJC-1295 WITH DAC | Four ascending single s.c. doses, then two or three weekly or fortnightly doses; 30 and 60 micrograms/kg named as better tolerated | 28 and 49 days | A single injection raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9-11 days, with a half-life of 5.8-8.1 days. That duration comes from the DAC and is not expected for the no-DAC compound in this blend. |
| Ionescu M et al.2006 · J Clin Endocrinol Metab · PMID 17018654 | DAC STUDY. Human, healthy men aged 20-40 (n not stated in the abstract). Tested CJC-1295 WITH DAC | 60 or 90 micrograms/kg, single injection | Sampling before and 1 week after injection | Growth hormone secretion rose while pulse frequency and size were unchanged. Trough GH rose 7.5-fold, mean GH 46% and IGF-I 45%, with no difference between the two doses. |
What these studies don't show: Trials do exist, though their reach is narrower than it first looks. Hand-picked groups and surrogate endpoints cap how far the findings can carry. The results apply to the setting studied and no further. Purity data confirms the vial's contents and says nothing about whether a compound works.
Every study links to its PubMed record. See all CJC-1295 + Ipamorelin studies in the research library →
CJC-1295 + Ipamorelin price in Canada: 10mg vial
Buy CJC 1295 Ipamorelin in Canada in a 10mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $69.00 | $6.90/mg |
Starter kit
Is CJC-1295 + Ipamorelin available in Canada?
There is no authorized CJC-1295 + Ipamorelin product in Canada: no DIN has been issued for it. This means Health Canada has not assessed it for safety, efficacy or quality. Borealis Peptides keeps it for in-vitro work and supplies it for no use in a living subject. How Health Canada treats research peptides →
Side effects reported in studies
Where a cited study commented on tolerability, that wording is reproduced unchanged below. Human work on this scale does not establish a safety profile.
CJC-1295 + Ipamorelin FAQ
What is CJC-1295 + Ipamorelin?
Both suppliers and the literature treat CJC-1295 + Ipamorelin as a two-peptide research blend: a GHRH analogue and a ghrelin receptor (GHS-R) agonist. The published work spans rat, human and DAC-study human models. Borealis Peptides provides it as lyophilised powder in 10 mg vials for in-vitro laboratory research. None of it is a medicine; it is not for human or veterinary use. Every study on this page is shown with its model and the result the authors recorded.
Where can I buy CJC-1295 + Ipamorelin in Canada?
Straight from Borealis Peptides, out of Canadian stock, so nothing has to cross a border to reach you. The format is 10 mg vials. Purity is checked by HPLC batch by batch, and we supply for laboratory research only. HPLC is run on each batch, and the certificate you receive points to the batch you were sent.
Is CJC-1295 + Ipamorelin legal in Canada?
There is no authorized CJC-1295 + Ipamorelin product in Canada: no DIN has been issued for it. This means Health Canada has not assessed it for safety, efficacy or quality. Borealis Peptides reserves it for in-vitro research and supplies it for use in no living subject. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so we understand it as a label on the intended supply, not a green light for use.
How much CJC-1295 + Ipamorelin should I use?
We do not field dosing questions. CJC-1295 + Ipamorelin is not provided for use in a person or an animal, so there is no dose to set out. What the page carries is the quantity each cited study used and the model it was used in, reproduced as the authors published it.
What human evidence is there for CJC-1295 + Ipamorelin?
Of the 8 cited studies, 2 are controlled trials in people and the rest are animal or cell work. Each row lists its model, the amount used and the authors' reported outcome, so every study can be weighed on its own terms instead of through a summary.
How is CJC-1295 + Ipamorelin stored?
Unopened, keep it at −20 °C in the dark. In solution it sits at 2–8 °C. The dry form is stable at room temperature, so no cold chain is needed in transit; refrigerate on arrival. A lyophilised peptide is degraded by light and temperature cycling rather than by how long it spends shipping.
How is the purity of CJC-1295 + Ipamorelin confirmed?
HPLC testing is done on every batch before sale, and the certificate points to the batch in your vial rather than to the product as a whole. Holding on to that batch number alongside your records is what lets an observation be reproduced later. Certificates can be supplied on request.
How does CJC-1295 + Ipamorelin compare with CJC-1295 (no DAC) and Ipamorelin?
Each carries its own published record, and comparing them comes down to reading both. CJC-1295 (no DAC) and Ipamorelin have 6 cited studies and 8 cited studies on their page against 8 here. Place the two evidence tables side by side and the difference shows plainly.
Why is CJC-1295 + Ipamorelin named in a Health Canada advisory?
Because it was one of the peptides seized from sellers offering unauthorized injectable products online. That advisory deals with material sold for people to inject without authorization. Borealis Peptides offers research material for in-vitro laboratory work and nothing for injection or for any use in a person, which is the distinction the advisory is drawn around.






